Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag for PARP inhibitor–induced thrombocytopenia in ovarian cancer (real‑world study)
ChiCTR2500102795Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hetrombopag in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Proportion of responding patients. Started May 2025; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2500102795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102795.